Overview
In this application note we show the analysis of a thermal denaturation-based formulation screen of the commercially available therapeutic antibody Infliximab with the FORMOscreen® plate and SUPR-DSF instrument. This screen was measured in triplicate in a single 384-well microplate in less than 2 hours. The barycentric mean (BCM) thermal denaturation curves were processed with a first derivative to find melting temperatures, which allowed us to come up with a single formulation that can be used with the antibody for future studies.
